DDDivya Dahiya

Divya Dahiya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Divya Dahiya has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinicopathological predictors of radioiodine response in differentiated high-grade thyroid carcinoma

    by Sohini Banerjee, Uma Nahar Saikia, Apurva Sood, Piyush Aggarwal, Soham Mukherjee, Pinaki Dutta, Divya Dahiya, Rijuneeta Gupta, Satyawati Mohindra, Jaimanti Bakshi

  • Efficacy and safety of peptide receptor radionuclide therapy in advanced foregut and hindgut neuroendocrine tumors: a real-world experience from a single institution

    by Piyush Aggarwal, Ashwani Sood, Divya Khosla, Rakesh Kapoor, Gaurav Prakash, Divya Dahiya, Sanjay Kumar Bhadada, Rama Walia, Rajesh Gupta, Bhagwant Rai Mittal

    Foregut and hindgut neuroendocrine tumors (NETs) contribute significantly to the global NET burden especially in Asian population; however, these cohorts are sparse and underrepresented in current trials assessing peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic (GEP) NETs. This single-centre study evaluates the efficacy and safety of PRRT in advanced foregut and hindgut NETs. Retrospective data evaluation of consecutive patients with biopsy-proven metastatic foregut (gastric, lung and thymic NETs) and hindgut NETs (colorectal, anal and sacral NETs) who underwent PRRT from 2014 to 2024 at a tertiary care hospital was done. Up to four cycles of 177Lu-DOTATATE (7.4 GBq/cycle) were administered intravenously every 6-8 weeks along with nephroprotection. Interim and end-of-treatment 68Ga-DOTANOC PET/CT scans were acquired for response evaluation, based on RECIST v1.1. Objective response rate (ORR), disease control rate (DCR), best biochemical response, toxicity profile, quality-of-life scores, progression-free survival (PFS) and overall survival (OS) were assessed. Thirty-four patients (median age-56 yrs) with foregut (n = 16) and hindgut (n = 18) NETs received a total of 111 cycles (range 1-4) of 177Lu-DOTATATE (median cumulative activity 26.5 GBq). The best ORR and DCR were 45% and 80%, median PFS was 29.7 months (95% CI, 20.3-39.1), and the 1- and 5-year OS rates were 93.8% (95% CI, 85.4-100) & 53.6% (95% CI, 28.6-78.6), respectively, after a median follow-up of 45.3 months. Grade 3 adverse events were observed in only five patients. PRRT appears to be safe and effective treatment modality in advanced foregut and hindgut NETs. More prospective trials are required to validate these findings in larger cohorts.

  • Aberrant Histone Methylation Profile in Patients with Sporadic Primary Hyperparathyroidism

    by Poonam Kumari, Sanjay Kumar Bhadada, Ashutosh Kumar Arya, Jyotdeep Kaur, Naresh Sachdeva, Uma Nahar Saikia, Divya Dahiya, Anoop Kumar, Chirag Kharbanda, Sudhaker D Rao

    Introduction: Primary hyperparathyroidism (PHPT) is a systemic endocrine disorder characterized by elevated PTH levels and hypercalcemia. Gene-specific epigenetic modifications like histone methylation play a pivotal role in PHPT by altering expression of parathyroid-specific genes. However, global histone modifications in parathyroid tumors and their implications for tumor behavior remain underexplored. Experimental Design: We performed comparative histone modification profiling in blood and tissue samples from sporadic parathyroid adenomas (PA; n = 30), atypical parathyroid tumors (APT; n = 05), and parathyroid carcinomas (PC; n = 05) along with controls using histone H3 multiplex immunoassay. Significantly dysregulated modifications were validated by Western blotting (WB), and expression data was correlated with clinicopathological features. We performed pathway enrichment analysis to elucidate molecular pathways potentially linked to histone H3 modifications in parathyroid tumorigenesis. Results: We observed dynamic alterations in histone H3 modifications of lysine (K) residues across parathyroid tumor phenotypes in blood and tissue samples. A reduction in H3K4 and H3K36 trimethylation (130%) compared to controls was observed. WB confirmed lower H3K4me3 (0.5 ± 0.4 vs 4.4 ± 0.7, P = .02; 0.4 ± 0.2 vs 4.4 ± 0.7, P = .004) and H3K36me3 (0.4 ± 0.2 vs 1.0 ± 0.3, P = .03; 0.2 ± 0.1 vs 1.0 ± 0.3, P = .02) in APT and PC than controls and higher H3K27me3 expression in PA (2.9 ± 1.2 vs 1.1 ± 0.21, P = .04), APT (4.2 ± 2.9 vs 1.1 ± 0.21, P = .007), and PC (6.9 ± 3.1 vs 1.1 ± 0.21, P = .0002) relative to controls. Pathway enrichment analysis identified molecular pathways, including calcium signaling, Wnt, and Hippo signaling, associated with histone H3 modifications. Conclusion: Increased expression of repressive H3K27me3 in blood and tissue samples, while decreased H3K4me3 and H3K36me3, suggest a shift toward transcriptional repression. Identifying their functional mechanisms may facilitate the discovery of novel insights for therapeutic targeting in parathyroid tumors.

  • Open Access

    Evaluation of quality of life in primary hyperparathyroidism patients: Pre- and post-parathyroidectomy outcomes in an Indian cohort

    by Manish Rohilla, Cherring Tandup, Divya Dahiya, Arunanshu Behera, Sanjay Kumar Bhadada, Manish Thakur, Sree Vani Paladugu

    Evaluation of quality of life in primary hyperparathyroidism patients: Pre- and post-parathyroidectomy outcomes in an Indian cohort - Turkish Journal of Surgery